AMBROSIO, Maria Rosaria
 Distribuzione geografica
Continente #
NA - Nord America 10.335
EU - Europa 4.419
AS - Asia 1.616
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
AF - Africa 1
Totale 16.389
Nazione #
US - Stati Uniti d'America 10.321
DE - Germania 1.811
CN - Cina 1.171
UA - Ucraina 804
IT - Italia 536
TR - Turchia 416
RU - Federazione Russa 307
GB - Regno Unito 297
FI - Finlandia 200
SE - Svezia 192
PL - Polonia 146
FR - Francia 48
BE - Belgio 45
CA - Canada 9
VN - Vietnam 8
IE - Irlanda 7
EU - Europa 6
RO - Romania 6
CZ - Repubblica Ceca 5
IN - India 5
NL - Olanda 5
BR - Brasile 4
IR - Iran 4
EC - Ecuador 3
MX - Messico 3
CH - Svizzera 2
CY - Cipro 2
ES - Italia 2
HK - Hong Kong 2
JP - Giappone 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
BD - Bangladesh 1
BG - Bulgaria 1
CR - Costa Rica 1
DK - Danimarca 1
GR - Grecia 1
KR - Corea 1
MA - Marocco 1
MD - Moldavia 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
VE - Venezuela 1
Totale 16.389
Città #
Woodbridge 1.316
Fairfield 1.155
Chandler 1.111
Jacksonville 897
Houston 767
Ashburn 715
Ann Arbor 506
Wilmington 442
Seattle 432
Cambridge 359
Izmir 278
Beijing 268
Nanjing 263
Princeton 226
Addison 216
San Diego 152
Warsaw 146
New York 138
Ferrara 130
Milan 120
Boardman 107
Shanghai 83
Shenyang 78
Hebei 70
Nanchang 70
Bremen 66
Washington 61
Dearborn 56
Changsha 46
Mountain View 46
Tianjin 46
Brussels 45
Jiaxing 43
Falls Church 37
Redwood City 35
Helsinki 31
Jinan 31
Kunming 30
London 28
Ningbo 24
Norwalk 23
Guangzhou 20
Des Moines 18
San Mateo 18
Bologna 17
Zhengzhou 17
Orange 15
Tappahannock 15
Auburn Hills 14
Hangzhou 12
Taizhou 12
Indiana 11
Hefei 10
Los Angeles 10
Carrara 9
Philadelphia 9
Dong Ket 8
Leawood 8
Monmouth Junction 8
Haikou 7
Lanzhou 7
Augusta 6
Changchun 6
Chicago 6
Redmond 6
Brno 5
Castelnuovo Rangone 5
Ferrara di Monte Baldo 5
Verona 5
Walnut 5
Ardabil 4
Dallas 4
San Francisco 4
Stockholm 4
Toronto 4
Chiswick 3
Cordovado 3
Fuzhou 3
Hounslow 3
Jinhua 3
Napoli 3
Paris 3
Reggio Emilia 3
Southwark 3
Terni 3
Voghera 3
Amsterdam 2
Andover 2
Bentivoglio 2
Bollate 2
Brembate 2
Chengdu 2
Cuauhtémoc 2
Dublin 2
Edinburgh 2
Hong Kong 2
Kilburn 2
Mereto Di Tomba 2
Mumbai 2
Munich 2
Totale 11.068
Nome #
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 235
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 156
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 154
Circadian profile of plasma calcitonin gene-related peptide in healthy man 151
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 148
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 144
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 135
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 132
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 131
null 130
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 129
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 128
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 124
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 124
Pituitary side effects of old and new drugs. 120
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 120
Cerebral aneurysm and acromegaly: a case report 119
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 118
null 118
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 117
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 115
null 114
In vitro testing of new somatostatin analogs on pituitary tumor cells 114
null 113
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI) 113
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 112
null 111
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 111
null 111
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. 110
null 108
null 106
null 106
null 106
null 105
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 104
null 104
Growth hormone and skeletal muscle function 103
Growth hormone excess promotes breast cancer chemoresistance 103
null 103
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 103
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 102
null 102
null 102
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 102
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 102
null 102
null 101
null 101
null 100
null 100
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 99
null 98
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 98
null 97
Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man 95
Le alterazioni pressorie nell'acromegalia: fattori umorali 94
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 93
Efficacy and safety of the new 60 mg formulation of the long acting somatostatin analog lanreotide in the treatment of acromegaly. 92
null 92
Acute lowering of plasma GH concentrations by somatostatin is associated with activation of pituitary-adrenal-axisin healthy young and elderly subjects 92
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 92
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 91
null 91
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 91
Diurnal rhythm of plasma catecholamines in acromegaly 90
PKCδ plays an important in regulating human medullary thyroid carcinoma cell viability 90
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 89
Blood GH-binding protein levels in premenopausal and postmenopausal women: role of body weight and estrogen levels 88
Endogenous estrogen status significantly influences the nutrition-related alterations in Growth Hormone-Binding protein levles in healthy women 88
Ovarian tumors secreting insulin 88
null 88
null 88
Growth hormone deficiency in succesfully treated acromegalic patients is not protective from cardiac complications 87
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone (GH)- releasing hormone function 87
Growth hormone induces chemoresistance in breast cancer cells 87
Prevalence and predictive factors of anterior hypopituitarism after ischemic stroke. 87
null 85
Cardiac and metabolic effects of chronic GH and IGF1 excess in young adults with pituitary gigantism 85
Prevalence of hypopituitarismin patients with cerebrovascular diseases 84
null 84
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 83
Glucose metabolism alterations in acromegaly 83
RISK FACTORS FOR DEVELOPING HYPOPITUITARISM AFTER STROKE 83
Delta opioid receptor involvement in endocrine pathophysiology 82
Antiproliferative effects of somatostatin analogs in pituitary adenomas 82
Occurrence of pituitary dysfunction following traumatic brain injury 81
A defective hypothalamic GHRH activity may contribute to declining GH secretion wuth age in man 81
Pattern of Growth Hormone secretion in closed head injured patients 81
Dopamine receptor 2 activation reduces cells viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 81
null 81
null 81
Systemic illness 80
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 80
Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study 80
Cerebrovascular disease and GH-IGF-i axis function 80
Post-stroke inflammatory response may influence pituitary function in patients with brain ischemic and hemorrhagic injury 79
Interrelationships between calcitonin gene-related peptide and sympathoadrenomedullary system: Effects of administration of epinephrine and norepinephrine in healthy man 79
Functional hypothalamic and drug-induced amenorrhea: an overview 79
Real-world study of everolimus in advanced progressive neuroendocrine tumors 79
Totale 10.267
Categoria #
all - tutte 56.292
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.114
Totale 60.406


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.608 0 0 0 0 0 0 0 0 190 334 348 736
2019/20203.128 547 92 87 447 184 397 235 308 210 375 195 51
2020/20212.021 187 145 119 256 72 212 64 235 66 269 288 108
2021/20221.981 58 208 114 57 89 90 96 90 79 162 187 751
2022/20232.373 234 221 90 310 328 341 131 208 284 30 121 75
2023/2024964 112 145 78 45 120 263 48 150 3 0 0 0
Totale 16.663